GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Price-to-Tangible-Book

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Price-to-Tangible-Book : 0.55 (As of Apr. 26, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics Price-to-Tangible-Book?

As of today (2024-04-26), Fresh Tracks Therapeutics's share price is $0.92057. Fresh Tracks Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.66. Hence, Fresh Tracks Therapeutics's Price to Tangible Book Ratio of today is 0.55.

The historical rank and industry rank for Fresh Tracks Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

FRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.53   Med: 0.74   Max: 1.89
Current: 0.55

During the past 13 years, Fresh Tracks Therapeutics's highest Price to Tangible Book Ratio was 1.89. The lowest was 0.53. And the median was 0.74.

FRTX's Price-to-Tangible-Book is ranked better than
93.11% of 1220 companies
in the Biotechnology industry
Industry Median: 2.68 vs FRTX: 0.55

A closely related ratio is called PB Ratio. As of today, Fresh Tracks Therapeutics's share price is $0.92057. Fresh Tracks Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.66. Hence, Fresh Tracks Therapeutics's P/B Ratio of today is 0.55.


Fresh Tracks Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Fresh Tracks Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Price-to-Tangible-Book Chart

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.68 1.54 1.10 0.63 0.53

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.40 0.52 0.53 0.53

Competitive Comparison of Fresh Tracks Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Price-to-Tangible-Book falls into.



Fresh Tracks Therapeutics Price-to-Tangible-Book Calculation

Fresh Tracks Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=0.92057/1.662
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Fresh Tracks Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
Executives
Monica E. Luchi officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy officer: General Counsel and CCO C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha officer: Chief Research & Dev. Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton officer: Chief Accounting Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown director, officer: Chief Executive Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer officer: COO and Secretary 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru director C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii officer: Chief Financial Officer
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja officer: Chief Medical Officer 121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy officer: Chief Business Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju director 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301